The Journal of Pain
Volume 6, Issue 2 , Pages 98-106, February 2005

Assessment of pain quality in chronic neuropathic and nociceptive pain clinical trials with the Neuropathic Pain Scale

  • Mark P. Jensen

      Affiliations

    • Department of Rehabilitation Medicine, University of Washington School of Medicine, Seattle, Washington
    • Multidisciplinary Pain Center, University of Washington Medical Center, Seattle, Washington
    • Corresponding Author InformationAddress reprint requests to Mark P. Jensen, PhD, Department of Rehabilitation Medicine, Box 356490, University of Washington School of Medicine, Seattle, WA 98195-6490.
    • ,
  • Robert H. Dworkin

      Affiliations

    • Department of Anesthesiology, University of Rochester Medical Center, Rochester, New York
    • ,
  • Arnold R. Gammaitoni

      Affiliations

    • Endo Pharmaceuticals, Inc, Chadds Ford, Pennsylvania.
    • ,
  • David O. Olaleye

      Affiliations

    • Endo Pharmaceuticals, Inc, Chadds Ford, Pennsylvania.
    • ,
  • Napoleon Oleka

      Affiliations

    • Endo Pharmaceuticals, Inc, Chadds Ford, Pennsylvania.
    • ,
  • Bradley S. Galer

      Affiliations

    • Endo Pharmaceuticals, Inc, Chadds Ford, Pennsylvania.

Received 29 June 2004; received in revised form 10 October 2004; accepted 10 November 2004.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 Supported by a grant from Endo Pharmaceuticals, Inc to the University of Rochester Office of Professional Education. M.P.J. has received research support or consulting fees in the past year from AstraZeneca, Endo Pharmaceuticals, Forest Pharmaceuticals, Pfizer, and Purdue Pharma. R.H.D. has received research support, consulting fees, or speakers bureau honoraria in the past year from Allergan, Alpharma, AstraZeneca, Bristol Myers-Squibb, Eli Lilly & Co, Endo Pharmaceuticals, EpiCept Corporation, GlaxoSmithKline, Johnson & Johnson, Merck KGaA, NeurogesX, Novartis Pharmaceuticals, Pfizer, Purdue Pharma, Reliant Pharmaceuticals, and UCB Pharma. A.R.G., N.O., and B.S.G. hold stock option in Endo Pharmaceuticals. Permission to use the Neuropathic Pain Scale can be obtained from the MAPI Research Institute (e-mail address: http://www.mapi-trust.org; B.S.G. and M.P.J. receive a portion of user fees for the NPS or PQAS charged by MAPI to industry (use by academic researchers is free).

PII: S1526-5900(04)01102-2

doi:10.1016/j.jpain.2004.11.002

Refers to erratum:

  • Erratum

    Mark P. Jensen, Robert H. Dworkin, Arnold R. Gammaitoni, David O. Olaleye, Napoleon Oleka, Bradley S. Galer
    The Journal of Pain September 2005 (Vol. 6, Issue 9, Page 637)

The Journal of Pain
Volume 6, Issue 2 , Pages 98-106, February 2005

Article Tools

* Image Usage & Resolution